Rt Hon JACINDA ARDERN: Yes. Forgive me, Mr Speaker, I'm just not entirely clear on the member—is she asking the question over whether or not we increased our order in January, when we had a completed contract? I'm just not clear on the content of the member's question. What the member will be aware of—and if I am given questions on notice, it enables me to give full time lines—is when we began our programme of ordering vaccines, we did take a portfolio approach. That was because there were a number of different vaccines in the market. Some—the RNA vaccines, for instance—were less well-known to the wider public health community. They were newer technological developments, and there were others that were more traditional. We took the option of ordering within each of those different portfolios to give us good coverage. As we progressed in some of those discussions, it was clear to us that there were some that were completing clinical trials earlier than others and some that had better data than others. So we made the decision ultimately to, in the end, go with a singular vaccine, because that gave us both logistical improvements, great efficacy across the board, and just the consistency for our population.